Canaccord lowered the firm’s price target on Akero Therapeutics to $56 from $59 and keeps a Buy rating on the shares. The firm updated its model to reflect the company’s latest financial resulst and the target reduction is mainly associated with its updated projections for FY2024 operating expenses.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKRO:
- Akero Therapeutics files automatic mixed securities shelf
- Akero Therapeutics reports Q1 EPS (90c), consensus (95c)
- Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- Akero Therapeutics appoints Gangloff as Chief Technology Officer
- Akero Therapeutics reinstated with a Neutral at BofA